HSPG2 and hepatocellular carcinoma: In addition, we validated the effects of C8018‐7840 in hepatocellular carcinoma (SNU‐449 and PLC), pancreatic ductal carcinoma (PANC‐1 and SUIT‐2), and breast cancer (MDA‐MB‐231 and MCF‐7) under CCL18 treatment.